EE04961B1 - N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis - Google Patents

N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Info

Publication number
EE04961B1
EE04961B1 EEP200100447A EEP200100447A EE04961B1 EE 04961 B1 EE04961 B1 EE 04961B1 EE P200100447 A EEP200100447 A EE P200100447A EE P200100447 A EEP200100447 A EE P200100447A EE 04961 B1 EE04961 B1 EE 04961B1
Authority
EE
Estonia
Prior art keywords
insulin resistance
propoxy
pyridine
oxide
methods
Prior art date
Application number
EEP200100447A
Other languages
English (en)
Estonian (et)
Inventor
βria K�rthy M
B�r� Katalin
βroly Nagy K
βszl� �r�gdi L
Cs βkai Zita
Szilbereky Jen�
βs Mogyor�si Tam
T�r�k Magdolna
βs Kom βromi Andr
M βrv βnyos Ede
βly Barab βs Mih
βlyn� Kardos Mih
βn Nagy Zolt
βszl� Kor βnyi L
Nagy Melinda
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200100447A publication Critical patent/EE200100447A/xx
Publication of EE04961B1 publication Critical patent/EE04961B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100447A 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis EE04961B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
EE200100447A EE200100447A (et) 2002-12-16
EE04961B1 true EE04961B1 (et) 2008-02-15

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100447A EE04961B1 (et) 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Country Status (27)

Country Link
US (1) US6649628B1 (de)
EP (1) EP1163224B1 (de)
JP (1) JP4689838B2 (de)
KR (1) KR100676124B1 (de)
AT (1) ATE237590T1 (de)
AU (1) AU779096B2 (de)
BG (1) BG65178B1 (de)
BR (1) BR0008969A (de)
CA (1) CA2360451C (de)
CZ (1) CZ297386B6 (de)
DE (1) DE60002187T2 (de)
DK (1) DK1163224T3 (de)
EE (1) EE04961B1 (de)
ES (1) ES2193055T3 (de)
HR (1) HRP20010584B1 (de)
HU (1) HUP9900475D0 (de)
IL (2) IL144866A0 (de)
NO (1) NO319793B1 (de)
PL (1) PL197692B1 (de)
PT (1) PT1163224E (de)
RS (1) RS50083B (de)
RU (1) RU2250901C2 (de)
SI (1) SI1163224T1 (de)
SK (1) SK287063B6 (de)
UA (1) UA72495C2 (de)
WO (1) WO2000050403A1 (de)
ZA (1) ZA200106488B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
PL371251A1 (en) 2002-01-11 2005-06-13 Biorex Kutato Es Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
EP2318032B1 (de) 2008-06-26 2012-04-04 Orphazyme APS Verwendung von hsp70 als regler der enzymatischen aktivität
EP2356988A4 (de) * 2008-11-18 2012-05-09 Santen Pharmaceutical Co Ltd Therapeutikum für chorioretinale degeneration mit pyridin-3-carbaldehyd o-(piperidin-1-yl-propyl)-oxim-derivat als wirkstoff
CN103338784A (zh) 2010-11-30 2013-10-02 奥菲泽米有限公司 用于增加Hsp70细胞内活性的方法
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US9861654B2 (en) * 2012-09-06 2018-01-09 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
DE202013012583U1 (de) 2012-09-14 2017-08-09 Saint-Gobain Glass France Scheibe mit einem elektrischen Anschlusselement
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
HUE054957T2 (hu) * 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
BR112018070653A2 (pt) * 2016-04-29 2019-02-05 Orphazyme A/S ingrediente farmacêutico ativo, e, composição
US20200085812A1 (en) 2017-05-24 2020-03-19 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
CA3101241A1 (en) 2018-05-28 2019-12-05 Orphazyme A/S Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
PT4171559T (pt) 2020-06-24 2025-12-16 Zevra Denmark As Arimoclomol para o tratamento da doença de gaucher
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
MX2023005954A (es) * 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
US20240115558A1 (en) 2020-12-24 2024-04-11 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
EE200100447A (et) 2002-12-16
CA2360451C (en) 2011-01-04
JP2002537384A (ja) 2002-11-05
DE60002187T2 (de) 2003-12-11
US6649628B1 (en) 2003-11-18
WO2000050403A1 (en) 2000-08-31
CZ297386B6 (cs) 2006-11-15
BG105837A (en) 2002-03-29
NO20014103D0 (no) 2001-08-23
IL144866A (en) 2007-07-04
PL197692B1 (pl) 2008-04-30
RU2250901C2 (ru) 2005-04-27
CZ20013053A3 (cs) 2002-01-16
IL144866A0 (en) 2002-06-30
HUP9900475D0 (en) 1999-04-28
KR20010102410A (ko) 2001-11-15
EP1163224A1 (de) 2001-12-19
DK1163224T3 (da) 2003-08-04
HRP20010584A2 (en) 2002-08-31
PL350915A1 (en) 2003-02-10
ES2193055T3 (es) 2003-11-01
EP1163224B1 (de) 2003-04-16
SI1163224T1 (en) 2003-08-31
HRP20010584B1 (en) 2010-08-31
JP4689838B2 (ja) 2011-05-25
SK287063B6 (sk) 2009-10-07
KR100676124B1 (ko) 2007-01-31
BR0008969A (pt) 2001-11-27
YU60301A (sh) 2004-05-12
PT1163224E (pt) 2003-07-31
SK11582001A3 (sk) 2001-12-03
AU779096B2 (en) 2005-01-06
ZA200106488B (en) 2002-08-07
ATE237590T1 (de) 2003-05-15
RS50083B (sr) 2009-01-22
NO20014103L (no) 2001-10-22
AU3182400A (en) 2000-09-14
CA2360451A1 (en) 2000-08-31
NO319793B1 (no) 2005-09-12
DE60002187D1 (de) 2003-05-22
UA72495C2 (uk) 2005-03-15
BG65178B1 (bg) 2007-05-31

Similar Documents

Publication Publication Date Title
EE04961B1 (et) N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
TW229205B (de)
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
CY1106409T1 (el) Παραγωγα κινολινης
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
SE0102147D0 (sv) New methods
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
TW200503999A (en) Therapeutic agents
BR9609932A (pt) Uso de derivados de prostano e a combinação dos mesmos com antibióticos no tratamento das infecções bacterianas
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
SE0202608D0 (sv) New sequences
DE60224078D1 (de) Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
IL172675A0 (en) Benzofuran derivatives and their use in the treatment of microbial infections

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110224